VitaCell Biologics
San Diego, United States· Est.
Is this your company? Claim your profile to update info and connect with investors.
Claim profilePrivate Company
Total funding raised: $650M
Overview
Developing off-the-shelf iPSC-derived cell therapies for regenerative medicine.
CardiovascularNeurology
Technology Platform
A platform for differentiating and manufacturing standardized, allogeneic cell therapies from engineered induced pluripotent stem cell (iPSC) lines.
Funding History
1Total raised:$650M
Series D$650M
Opportunities
Potential to provide scalable, cost-effective regenerative treatments for large patient populations with chronic diseases.
Risk Factors
Faces significant scientific, manufacturing, and clinical risks, including potential for tumorigenicity and immune rejection of allogeneic cells.
Competitive Landscape
Competes in the allogeneic cell therapy arena with other iPSC-focused biotechs and companies using mesenchymal stem cells.